HomepageTTNP • NASDAQ
add
Titan Pharmaceuticals, Inc. common stock
Vorige slotkoers
$Â 4,80
Dag-range
$Â 4,53 - $Â 4,81
Jaar-range
$Â 4,24 - $Â 14,80
Beurswaarde
4,27Â mln. USD
Gem. volume
19,75K
Koers/winst
-
Dividendrendement
-
Primaire beurs
NASDAQ
Marktnieuws
.INX
0,40%
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(USD) | jun 2024info | Wijziging j-o-j |
---|---|---|
Opbrengst | — | — |
Bedrijfskosten | 2,07Â mln. | 68,76% |
Netto inkomsten | -2,09Â mln. | -31,97% |
Netto winstmarge | — | — |
Winst per aandeel | — | — |
EBITDA | -2,07Â mln. | -33,70% |
Effectief belastingtarief | — | — |
Balans
Totale activa
Totale passiva
(USD) | jun 2024info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 4,09Â mln. | 3.797,14% |
Totale activa | 4,35Â mln. | 435,71% |
Totale passiva | 356,00K | -80,72% |
Totaal aandelenvermogen | 3,99 mln. | — |
Uitstaande aandelen | 914,23K | — |
Koers-boekwaardeverhouding | 1,10 | — |
Rendement op activa | -94,31% | — |
Rendement op kapitaal | -102,53% | — |
Kasstroom
Nettomutatie in liquide middelen
(USD) | jun 2024info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | -2,09Â mln. | -31,97% |
Operationele kasstroom | -2,07Â mln. | -85,97% |
Kasstroom uit beleggingen | — | — |
Kasstroom uit financiering | — | — |
Nettomutatie in liquide middelen | -2,07Â mln. | -85,97% |
Vrije kasstroom | -1,27Â mln. | -22,46% |
Over
Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in San Francisco, CA developing proprietary therapeutics primarily for the treatment of central nervous system disorders. In September 2018, Titan Pharmaceuticals underwent an IPO wherein it raised $9.5 million in gross proceeds. In the same month, it also posted approximately $1.7 million in revenue, in large part drawn from its licensing for its European intellectual property rights for Probuphine to the Italian pharmaceutical company Molteni - a leading European opioid manufacturer and also a subsidiary of the German Pharmaceutical juggernaut Merck Group.
Titan's principal asset is Probuphine, a slow-release implant formulation of buprenorphine for the treatment of opioid addiction or chronic pain. FDA Approval was granted on 26 May 2016. It was licensed to Braeburn Pharmaceuticals for marketing and commercialization. Wikipedia
Opgericht
1991
Hoofdvestiging
Website
Werknemers
4